Bio-Techne announces quarterly dividend pending Merck KGaA acquisition status
Bio-Techne Corporation will pay a dividend of $0.08 per share, contingent on the status of its pending acquisition by Merck KGaA as of November 13.
Bio-Techne Corporation has declared a cash dividend of $0.08 per share for the fiscal quarter ending September 30, 2026. The payment is scheduled for distribution on November 23, 2026, to shareholders of record as of the close of business on November 13, 2026.
The dividend declaration includes a specific condition: payment is contingent upon the company’s pending transaction with Germany-based Merck KGaA not closing on or before the November 13 record date. Shareholders have previously approved the acquisition, which remains the primary driver for the company's near-term corporate structure.
Bio-Techne provides research tools and clinical diagnostic reagents to the life sciences sector. The company reported net sales exceeding $1.2 billion in fiscal 2026 and operates with a global workforce of approximately 3,000 employees. The board stated that future dividend considerations will be evaluated on a quarterly basis.